These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4688 related articles for article (PubMed ID: 1536778)

  • 1. Responses of B16 melanoma cell lines, F1 and F10, to hyperthermia, lymphokine-activated killer cells and a combination of both in vitro.
    Nakayama J; Moroi Y; Toshitani A; Taniguchi S; Okamoto-Inoue M; Hori Y
    Br J Dermatol; 1992 Feb; 126(2):131-6. PubMed ID: 1536778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of B16 melanoma sublines to lymphokine-activated killer cells as determined by 51Cr-release and clonogenic assays.
    Tzeng JJ; Barth RF
    J Immunol Methods; 1990 Apr; 128(2):257-66. PubMed ID: 2324514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of in vitro cytolytic activity of LAK cells with heated ATL-derived cell lines.
    Nakayama J; Toshitani A; Hattori T; Moroi Y; Hori Y
    J Dermatol; 1993 Aug; 20(8):457-65. PubMed ID: 8245306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides.
    Nakayama J; Urabe K; Tsuchida T; Urabe A; Terao H; Taniguchi S; Hori Y
    J Dermatol; 1995 Aug; 22(8):549-59. PubMed ID: 7560451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct and non-cross-reactive epitopes are recognized on B16 melanoma by LAK cells and anti-B16 monoclonal antibodies.
    Tzeng JJ; Barth RF; Johnson CW; Adams DM
    Proc Soc Exp Biol Med; 1990 Apr; 193(4):285-92. PubMed ID: 1690893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro comparison between mouse B16 and human melanoma cell lines of the expression of ICAM-1 induced by cytokines and/or hyperthermia.
    Nakayama J; Guan XC; Nakashima M; Mashino T; Hori Y
    J Dermatol; 1997 Jun; 24(6):351-60. PubMed ID: 9241963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.
    Werthmöller N; Frey B; Rückert M; Lotter M; Fietkau R; Gaipl US
    Int J Hyperthermia; 2016; 32(1):23-30. PubMed ID: 26754406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity to hyperthermia of the F1 and F10 B16 melanoma variants.
    Leibovici J; Klorin G; Huszar M; Hoenig S; Michowitz M
    Int J Exp Pathol; 1991 Apr; 72(2):139-50. PubMed ID: 2015198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
    Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
    Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility study of high-temperature thermoseed inductive hyperthermia in melanoma treatment.
    Xia QS; Liu X; Xu B; Zhao TD; Li HY; Chen ZH; Xiang Q; Geng CY; Pan L; Hu RL; Qi YJ; Sun GF; Tang JT
    Oncol Rep; 2011 Apr; 25(4):953-62. PubMed ID: 21234522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells.
    Basse PH; Nannmark U; Johansson BR; Herberman RB; Goldfarb RH
    J Natl Cancer Inst; 1991 Jul; 83(13):944-50. PubMed ID: 2067037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model.
    Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
    Life Sci; 2002 Jan; 70(7):791-8. PubMed ID: 11833741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery.
    Da Costa ML; Redmond HP; Bouchier-Hayes DJ
    J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
    Fujiwara T; Grimm EA
    J Immunol; 1992 May; 148(9):2941-6. PubMed ID: 1374105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
    Donskov F; Basse PH; Hokland M
    Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 235.